How dangerous is sleep apnoea?
Moderate to severe sleep apnoea substantially increases your risk of cardiovascular disease, diabetes and depression. Treatment with a CPAP device demonstrably reduces those risks.
Sleep apnoea is widespread but is frequently missed. Globally, an estimated nearly one billion people are affected. In a large Swiss population study, almost half of men (49.7%) and just over a quarter of women (23.4%) had a moderate to severe form1,2.
The greatest dangers involve the heart. More than 15 breathing interruptions per hour significantly raises your risk of coronary artery disease, heart failure, stroke and cardiac arrhythmias. In one study, people with sleep apnoea had nearly twice the chance of stroke or death, even after correcting for smoking, diabetes and high blood pressure3,4.
Beyond the heart, there are further risks. People with the most severe forms had a 60% higher chance of high blood pressure, twice the chance of diabetes, 2.8 times the chance of metabolic syndrome and nearly twice the chance of depression2. There also appears to be a link with joint problems: people with osteoarthritis of the knee, hip or hand are around 45 to 50% more likely to develop sleep apnoea, although that is not yet a proven causal relationship5.
Do you also suffer from insomnia on top of sleep apnoea? Then your risk is even higher. That combination, known as COMISA, was associated with a 47% higher chance of death over 15 years of follow-up compared with people who had neither condition. Notably, sleep apnoea or insomnia alone did not produce a significantly increased mortality in that same study. It is precisely the combination that appears to be dangerous6.
The good news is that treatment works. A CPAP device, a mask that keeps your airways open during the night, lowers blood pressure, reduces cardiac arrhythmias and decreases daytime sleepiness. This effect occurs when the device is used for at least four hours per night on more than 70% of nights4. If you suspect breathing interruptions, have them investigated; early treatment produces real health gains1,7.
Most of the evidence comes from observational and associative research; causality has not been definitively proven for the risk outcomes. No randomised trials were used for the risk estimates. The effects of CPAP are considered probably causal, but are not supported by precise figures in the sources used. Global prevalence figures come from population studies using broad definitions.